You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHydrochlorothiazide
Accession NumberDB00999  (APRD00092)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It has been used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism. [PubChem]
Structure
Thumb
Synonyms
Esidrix
HCTZ
Microzide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-hydrochlorothiazideTablet12.5 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-hydrochlorothiazideTablet25 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-hydrochlorothiazideTablet50 mgOralAvanstra Inc2011-10-112014-08-21Canada
Bio-hydrochlorothiazideTablet50 mgOralBiomed Pharma2003-04-11Not applicableCanada
Bio-hydrochlorothiazideTablet100 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-hydrochlorothiazideTablet25 mgOralBiomed Pharma2003-04-11Not applicableCanada
Diuchlor H Tab 50mgTablet50 mgOralMedic Laboratory LtÉe1964-12-311996-09-09Canada
Dom-hydrochlorothiazideTablet25 mgOralBiomed Pharma2004-02-062013-08-02Canada
Dom-hydrochlorothiazideTablet12.5 mgOralDominion Pharmacal2006-08-022007-11-02Canada
Dom-hydrochlorothiazideTablet50 mgOralBiomed Pharma2004-02-062013-08-02Canada
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralREMEDYREPACK INC.2014-07-14Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralActavis Pharma, Inc.1996-12-27Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1Oralbryant ranch prepack1996-12-27Not applicableUs
HydrochlorothiazideTablet50 mgOralSanis Health Inc2011-02-08Not applicableCanada
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralSTAT Rx USA LLC1996-12-27Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1996-12-27Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralPreferred Pharmaceuticals Inc.2015-08-14Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-21Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralPd Rx Pharmaceuticals, Inc.1996-12-27Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralBlenheim Pharmacal, Inc.2011-12-20Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralMc Kesson Contract Packaging1996-12-27Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralREMEDYREPACK INC.2013-03-27Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralProficient Rx LP1996-12-27Not applicableUs
HydrochlorothiazideTablet25 mgOralSanis Health Inc2011-02-08Not applicableCanada
HydrochlorothiazideTablet25 mg/1OralBlenheim Pharmacal, Inc.2010-04-08Not applicableUs
Hydrochlorothiazide 100 TabTablet100 mgOralPro Doc Limitee1981-12-312009-07-23Canada
Hydrochlorothiazide 100mg TabletsTablet100 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Hydrochlorothiazide 25mg TabletsTablet25 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Hydrochlorothiazide 50Tablet50 mgOralPro Doc Limitee1972-12-312010-07-13Canada
Hydrochlorothiazide 50mg TabletsTablet50 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Hydrochlorothiazide Tab 25mgTablet25 mgOralPro Doc Limitee1975-12-31Not applicableCanada
Hydrochlorothiazide Tab 25mgTablet25 mgOralDuchesnay Inc1978-12-312003-07-18Canada
Hydrochlorothiazide Tab 50mgTablet50 mgOralDuchesnay Inc1978-12-312003-07-18Canada
Hydrochlorothiazide Tablets 25mgTablet25 mgOralD.C. Labs Limited1971-12-312003-07-11Canada
Hydrochlorothiazide Tablets 50mgTablet50 mgOralD.C. Labs Limited1971-12-312003-07-11Canada
Hydrodiuril Tab 100mgTablet100 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1976-12-311998-08-14Canada
Hydrodiuril Tab 25mgTablet25 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-312001-06-04Canada
Hydrodiuril Tab 50mgTablet50 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1959-12-312000-08-03Canada
MicrozideCapsule, gelatin coated12.5 mg/1OralWatson Pharma, Inc.1996-12-27Not applicableUs
Mint-hydrochlorothiazideTablet12.5 mgOralMint Pharmaceuticals Inc2014-07-23Not applicableCanada
Mint-hydrochlorothiazideTablet25 mgOralMint Pharmaceuticals Inc2014-07-23Not applicableCanada
Mint-hydrochlorothiazideTablet50 mgOralMint Pharmaceuticals Inc2014-07-23Not applicableCanada
Neo Codema 25mgTablet25 mgOralNeolab Inc1960-12-311997-08-12Canada
Neo Codema 50mgTablet50 mgOralNeolab Inc1960-12-311997-08-12Canada
Ntp-hydrochlorothiazideTablet25 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-hydrochlorothiazideTablet50 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-hydroTablet25 mgOralNu Pharm Inc2004-03-242012-09-04Canada
Nu-hydroTablet12.5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-hydroTablet50 mgOralNu Pharm Inc2004-03-242012-09-04Canada
PHL-hydrochlorothiazideTablet12.5 mgOralPharmel Inc2006-07-212007-11-02Canada
PMS-hydrochlorothiazideTablet100 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-hydrochlorothiazideTablet12.5 mgOralPharmascience Inc2005-12-22Not applicableCanada
PMS-hydrochlorothiazideTablet25 mgOralPharmascience Inc2003-12-10Not applicableCanada
PMS-hydrochlorothiazideTablet50 mgOralPharmascience Inc2003-12-10Not applicableCanada
Teva-hydrochlorothiazideTablet25 mgOralTeva Canada Limited1968-12-31Not applicableCanada
Teva-hydrochlorothiazideTablet50 mgOralTeva Canada Limited1968-12-31Not applicableCanada
UrozideTablet50 mgOralBiomed Pharma1973-12-31Not applicableCanada
UrozideTablet100 mgOralBiomed Pharma1979-12-31Not applicableCanada
UrozideTablet25 mgOralBiomed Pharma1985-10-18Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Hydro Tab 100mgTablet100 mgOralApotex Inc1988-12-31Not applicableCanada
Apo Hydro Tab 25mgTablet25 mgOralApotex Inc1975-12-31Not applicableCanada
Apo Hydro Tab 50mgTablet50 mgOralApotex Inc1974-12-31Not applicableCanada
Apo-hydroTablet12.5 mgOralApotex Inc2009-07-02Not applicableCanada
HydrochlorothiazideTablet25 mg/1OralCitron Pharma LLC2007-07-20Not applicableUs
HydrochlorothiazideTablet25 mg/1OralUnichem Pharmaceuticals (USA), Inc.2009-07-02Not applicableUs
HydrochlorothiazideTablet25 mg/1OralPreferred Pharmaceuticals Inc.2016-12-06Not applicableUs
HydrochlorothiazideTablet25 mg/1OralRebel Distributors Corp2010-08-16Not applicableUs
HydrochlorothiazideTablet25 mg/1OralREMEDYREPACK INC.2013-05-13Not applicableUs
HydrochlorothiazideTablet25 mg/1OralInternational Laboratories, Inc.2015-03-16Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralCitron Pharma LLC2007-09-19Not applicableUs
HydrochlorothiazideTablet50 mg/1OralREMEDYREPACK INC.2015-12-23Not applicableUs
HydrochlorothiazideTablet25 mg/1OralTYA Pharmaceuticals2010-08-20Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralRed Pharm Drug Inc.2002-09-17Not applicableUs
HydrochlorothiazideTablet50 mg/1OralLannett Company, Inc.2007-05-01Not applicableUs
HydrochlorothiazideTablet50 mg/1OralAccord Healthcare Inc.2013-01-15Not applicableUs
HydrochlorothiazideTablet50 mg/1OralREMEDYREPACK INC.2011-09-272016-11-08Us
HydrochlorothiazideCapsule12.5 mg/1OralBlenheim Pharmacal, Inc.2013-10-07Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralUnit Dose Services2008-02-11Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralNationwide Pharmaceutical, Llc2015-03-01Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralAv Kare, Inc.2016-09-12Not applicableUs
HydrochlorothiazideTablet50 mg/1OralNu Care Pharmaceuticals, Inc.2013-04-10Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralMylan Pharmaceuticals Inc.2000-02-07Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralHeritage Pharmaceuticals Inc2009-06-20Not applicableUs
HydrochlorothiazideTablet50 mg/1OralScie Gen Pharmaceuticals, Inc.2014-02-05Not applicableUs
HydrochlorothiazideTablet25 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralCardinal Health2007-06-28Not applicableUs
HydrochlorothiazideTablet25 mg/1OralGolden State Medical Supply, Inc2014-07-23Not applicableUs
HydrochlorothiazideTablet25 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2002-03-29Not applicableUs
HydrochlorothiazideTablet50 mg/1OralContract Pharmacy Services Pa2010-11-09Not applicableUs
HydrochlorothiazideTablet25 mg/1OralWest ward Pharmaceutical Corp2006-08-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralBlenheim Pharmacal, Inc.2015-04-06Not applicableUs
HydrochlorothiazideTablet50 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-06-01Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralPreferred Pharmaceuticals, Inc.2012-07-27Not applicableUs
HydrochlorothiazideTablet25 mg/1OralMed Vantx, Inc.1973-01-12Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralLegacy Pharmaceutical Packaging2002-09-17Not applicableUs
HydrochlorothiazideTablet25 mg/1OralBlenheim Pharmacal, Inc.2010-12-01Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralHeritage Pharmaceuticals Inc.2010-12-10Not applicableUs
HydrochlorothiazideTablet25 mg/1OralA S Medication Solutions Llc2009-07-02Not applicableUs
HydrochlorothiazideTablet25 mg/1OralREMEDYREPACK INC.2015-04-22Not applicableUs
HydrochlorothiazideTablet50 mg/1OralREMEDYREPACK INC.2016-05-06Not applicableUs
HydrochlorothiazideTablet50 mg/1OralTeva Pharmaceuticals Usa, Inc.1980-01-07Not applicableUs
HydrochlorothiazideTablet25 mg/1OralPd Rx Pharmaceuticals, Inc.2002-03-29Not applicableUs
HydrochlorothiazideTablet25 mg/1OralH.J. Harkins Company, Inc.2010-08-20Not applicableUs
HydrochlorothiazideTablet50 mg/1OralA S Medication Solutions Llc2002-03-29Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralClinical Solutions Wholesale2010-03-15Not applicableUs
HydrochlorothiazideTablet50 mg/1OralProficient Rx LP2007-06-01Not applicableUs
HydrochlorothiazideTablet50 mg/1OralSt Marys Medical Park Pharmacy2013-07-10Not applicableUs
HydrochlorothiazideTablet25 mg/1OralReady Meds1980-11-05Not applicableUs
HydrochlorothiazideTablet50 mg/1OralContract Pharmacy Services Pa2010-08-16Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralActavis Elizabeth LLC2007-03-12Not applicableUs
HydrochlorothiazideTablet50 mg/1OralSTAT Rx USA LLC2010-04-02Not applicableUs
HydrochlorothiazideTablet50 mg/1OralREMEDYREPACK INC.2013-10-082016-11-30Us
HydrochlorothiazideCapsule12.5 mg/1OralLife Line Home Care Services, Inc.2012-02-08Not applicableUs
HydrochlorothiazideTablet50 mg/1OralQualitest Pharmaceuticals2002-03-29Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralA S Medication Solutions2010-03-15Not applicableUs
HydrochlorothiazideTablet25 mg/1OralLeading Pharma, Llc2007-03-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralLegacy Pharmaceutical Packaging, Llc1973-01-12Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralAidarex Pharmaceuticals LLC2002-09-17Not applicableUs
HydrochlorothiazideTablet25 mg/1OralNorthwind Pharmaceuticals, LLC2014-08-21Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
HydrochlorothiazideTablet50 mg/1OralPd Rx Pharmaceuticals, Inc.2002-03-29Not applicableUs
HydrochlorothiazideTablet25 mg/1OralREMEDYREPACK INC.2012-08-29Not applicableUs
HydrochlorothiazideTablet50 mg/1OralCitron Pharma LLC2007-07-20Not applicableUs
HydrochlorothiazideTablet50 mg/1OralUnichem Pharmaceuticals (USA), Inc.2009-07-02Not applicableUs
HydrochlorothiazideTablet25 mg/1OralCentral Texas Community Health Centers2002-03-29Not applicableUs
HydrochlorothiazideTablet50 mg/1OralRebel Distributors Corp2010-08-20Not applicableUs
HydrochlorothiazideTablet50 mg/1OralREMEDYREPACK INC.2013-08-21Not applicableUs
HydrochlorothiazideTablet50 mg/1OralInternational Labs, Inc.2011-08-01Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralSun Pharmaceutical Industries, Inc.2014-04-17Not applicableUs
HydrochlorothiazideTablet25 mg/1OralDIRECT RX2015-01-01Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralAurobindo Pharma Limited2007-09-19Not applicableUs
HydrochlorothiazideTablet50 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-03-29Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralLannett Company, Inc.2012-01-27Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralRebel Distributors Corp2007-02-27Not applicableUs
HydrochlorothiazideTablet25 mg/1OralREMEDYREPACK INC.2012-03-152016-10-15Us
HydrochlorothiazideTablet25 mg/1OralREMEDYREPACK INC.2010-11-302016-10-13Us
HydrochlorothiazideTablet50 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralREMEDYREPACK INC.2016-03-14Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralA S Medication Solutions2002-09-17Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralPreferred Pharmaceuticals Inc.2016-09-30Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralUnichem Pharmaceuticals (USA), Inc.2010-03-15Not applicableUs
HydrochlorothiazideTablet25 mg/1OralREMEDYREPACK INC.2013-03-012016-11-01Us
HydrochlorothiazideTablet50 mg/1OralUnit Dose Services2010-08-20Not applicableUs
HydrochlorothiazideTablet50 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralCardinal Health2012-04-02Not applicableUs
HydrochlorothiazideTablet50 mg/1OralGolden State Medical Supply, Inc2014-07-23Not applicableUs
HydrochlorothiazideTablet50 mg/1OralExcellium Pharmaceutical Inc.2007-06-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralContract Pharmacy Services Pa2010-03-09Not applicableUs
HydrochlorothiazideTablet50 mg/1OralWest ward Pharmaceutical Corp1977-02-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralApotheca, Inc.1996-12-21Not applicableUs
HydrochlorothiazideTablet25 mg/1OralJUBILANT CADISTA PHARMACEUTICALS, INC.2007-10-26Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralProficient Rx LP2013-01-15Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralMed Vantx, Inc.2011-04-07Not applicableUs
HydrochlorothiazideTablet25 mg/1OralLegacy Pharmaceutical Packaging2002-03-29Not applicableUs
HydrochlorothiazideTablet25 mg/1OralBlenheim Pharmacal, Inc.2011-06-15Not applicableUs
HydrochlorothiazideTablet50 mg/1OralHeritage Pharmaceuticals Inc.2010-08-20Not applicableUs
HydrochlorothiazideTablet50 mg/1OralA S Medication Solutions Llc2009-07-02Not applicableUs
HydrochlorothiazideTablet25 mg/25mgOralWestminster Pharmaceuticals, Llc2016-02-01Not applicableUs
HydrochlorothiazideTablet50 mg/1OralCarilion Materials Management1980-01-07Not applicableUs
HydrochlorothiazideTablet25 mg/1OralREMEDYREPACK INC.2016-09-23Not applicableUs
HydrochlorothiazideTablet50 mg/1OralA S Medication Solutions2013-04-10Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralPd Rx Pharmaceuticals, Inc.2012-01-27Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
HydrochlorothiazideTablet50 mg/1OralPhysicians Total Care, Inc.1992-09-22Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralPd Rx Pharmaceuticals, Inc.2006-08-01Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralREMEDYREPACK INC.2015-04-16Not applicableUs
HydrochlorothiazideTablet50 mg/1OralReady Meds1980-11-05Not applicableUs
HydrochlorothiazideTablet25 mg/1OralDAVA Pharmaceuticals, Inc.1980-11-052016-11-15Us
HydrochlorothiazideTablet25 mg/1OralLiberty Pharmaceuticals, Inc.2008-01-29Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralAccord Healthcare Inc.2013-01-15Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralREMEDYREPACK INC.2011-05-132016-11-30Us
HydrochlorothiazideTablet25 mg/1OralMc Kesson Contract Packaging2011-10-12Not applicableUs
HydrochlorothiazideTablet25 mg/1OralHeritage Pharmaceuticals Inc.2015-01-15Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralA S Medication Solutions2013-04-18Not applicableUs
HydrochlorothiazideTablet25 mg/1OralExelan Pharmaceuticals Inc.2016-08-30Not applicableUs
HydrochlorothiazideTablet50 mg/1OralLegacy Pharmaceutical Packaging, Llc1980-01-07Not applicableUs
HydrochlorothiazideTablet25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-08-01Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralNorthwind Pharmaceuticals, LLC2014-09-14Not applicableUs
HydrochlorothiazideTablet25 mg/1OralRebel Distributors Corp2006-08-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-28Not applicableUs
HydrochlorothiazideTablet25 mg/1OralREMEDYREPACK INC.2014-10-24Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralClinical Solutions Wholesale, Llc2010-03-15Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralDIRECT RX2014-01-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralVensun Pharmaceuticals, Inc.2014-10-18Not applicableUs
HydrochlorothiazideTablet25 mg/1OralREMEDYREPACK INC.2013-07-08Not applicableUs
HydrochlorothiazideTablet25 mg/1OralInternational Labs, Inc.2011-08-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralClinical Solutions Wholesale2010-03-15Not applicableUs
HydrochlorothiazideTablet25 mg/1OralProficient Rx LP2010-08-20Not applicableUs
HydrochlorothiazideTablet25 mg/1OralAurobindo Pharma Limited2007-07-20Not applicableUs
HydrochlorothiazideTablet25 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-03-29Not applicableUs
HydrochlorothiazideTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-03-29Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralWest ward Pharmaceutical Corp2007-11-26Not applicableUs
HydrochlorothiazideTablet50 mg/1OralApotheca, Inc.2009-06-30Not applicableUs
HydrochlorothiazideTablet25 mg/1OralREMEDYREPACK INC.2011-05-092016-10-19Us
HydrochlorothiazideTablet25 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-30Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralQualitest Pharmaceuticals2002-09-17Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralA S Medication Solutions2010-03-15Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralAvera Mc Kennan Hospital2015-12-02Not applicableUs
HydrochlorothiazideTablet25 mg/1OralRed Pharm Drug, Inc.2007-06-01Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralREMEDYREPACK INC.2013-03-182016-10-13Us
HydrochlorothiazideCapsule12.5 mg/1OralMylan Institutional Inc.2005-11-01Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralCardinal Health2010-10-29Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralSt Marys Medical Park Pharmacy2013-05-15Not applicableUs
HydrochlorothiazideTablet25 mg/1OralExcellium Pharmaceutical Inc.2007-06-01Not applicableUs
HydrochlorothiazideTablet50 mg/1OralContract Pharmacy Services Pa2010-03-09Not applicableUs
HydrochlorothiazideTablet25 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralPhysicians Total Care, Inc.1995-10-04Not applicableUs
HydrochlorothiazideTablet50 mg/1OralJUBILANT CADISTA PHARMACEUTICALS, INC.2007-10-26Not applicableUs
HydrochlorothiazideTablet25 mg/1Oralbryant ranch prepack2010-08-20Not applicableUs
HydrochlorothiazideTablet25 mg/1OralDispensing Solutions, Inc.2003-03-29Not applicableUs
HydrochlorothiazideTablet50 mg/1OralPreferred Pharmaceuticals Inc.2015-10-07Not applicableUs
HydrochlorothiazideTablet25 mg/1OralBlenheim Pharmacal, Inc.2013-03-28Not applicableUs
HydrochlorothiazideTablet25 mg/1OralHeritage Pharmaceuticals Inc.2010-08-20Not applicableUs
HydrochlorothiazideTablet50 mg/1OralA S Medication Solutions Llc2007-07-20Not applicableUs
HydrochlorothiazideTablet50 mg/50mgOralWestminster Pharmaceuticals, Llc2016-02-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-04-10Not applicableUs
HydrochlorothiazideTablet25 mg/1OralProficient Rx LP2013-04-10Not applicableUs
HydrochlorothiazideTablet25 mg/1OralA S Medication Solutions2002-03-29Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-09-17Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-03-15Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralNorthwind Pharmaceuticals, LLC2015-03-06Not applicableUs
HydrochlorothiazideTablet50 mg/1OralInternational Laboratories, Inc.2015-05-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-07-02Not applicableUs
HydrochlorothiazideTablet50 mg/1OralREMEDYREPACK INC.2015-09-17Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralTYA Pharmaceuticals2010-12-10Not applicableUs
HydrochlorothiazideTablet50 mg/1OralDAVA Pharmaceuticals, Inc.1980-11-052016-11-15Us
HydrochlorothiazideTablet25 mg/1OralLannett Company, Inc.2007-05-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralAccord Healthcare Inc.2013-01-15Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralREMEDYREPACK INC.2011-08-302016-11-18Us
HydrochlorothiazideCapsule12.5 mg/1OralGreenstone LLC2007-09-192015-12-31Us
HydrochlorothiazideTablet50 mg/1OralHeritage Pharmaceuticals Inc.2015-01-15Not applicableUs
HydrochlorothiazideTablet25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-04-10Not applicableUs
HydrochlorothiazideTablet50 mg/1OralExelan Pharmaceuticals Inc.2016-08-30Not applicableUs
HydrochlorothiazideTablet25 mg/1OralUnit Dose Services2007-05-01Not applicableUs
HydrochlorothiazideTablet50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-03-29Not applicableUs
HydrochlorothiazideTablet50 mg/1OralRebel Distributors Corp1977-02-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralA S Medication Solutions Llc2009-07-02Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralREMEDYREPACK INC.2015-01-06Not applicableUs
HydrochlorothiazideTablet25 mg/1OralClinical Solutions Wholesale, Llc2009-07-02Not applicableUs
HydrochlorothiazideTablet25 mg/1OralTeva Pharmaceuticals Usa, Inc.1973-01-12Not applicableUs
HydrochlorothiazideTablet50 mg/1OralVensun Pharmaceuticals, Inc.2014-10-18Not applicableUs
HydrochlorothiazideTablet50 mg/1OralREMEDYREPACK INC.2013-06-24Not applicableUs
HydrochlorothiazideTablet25 mg/1OralA S Medication Solutions Llc2002-03-29Not applicableUs
HydrochlorothiazideTablet50 mg/1OralClinical Solutions Wholesale2010-03-15Not applicableUs
HydrochlorothiazideTablet25 mg/1OralProficient Rx LP2007-06-01Not applicableUs
HydrochlorothiazideTablet50 mg/1OralAurobindo Pharma Limited2007-07-20Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralAmerican Health Packaging2013-07-08Not applicableUs
HydrochlorothiazideTablet25 mg/1OralContract Pharmacy Services Pa2010-08-16Not applicableUs
HydrochlorothiazideTablet25 mg/1OralKAISER FOUNDATION HOSPITALS2010-06-07Not applicableUs
HydrochlorothiazideTablet25 mg/1OralSTAT Rx USA LLC2002-03-29Not applicableUs
HydrochlorothiazideTablet25 mg/1OralREMEDYREPACK INC.2011-07-202016-10-29Us
HydrochlorothiazideTablet25 mg/1OralPreferred Pharmaceuticals, Inc.2015-05-05Not applicableUs
HydrochlorothiazideTablet25 mg/1OralQualitest Pharmaceuticals2002-03-29Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralA S Medication Solutions2013-04-18Not applicableUs
HydrochlorothiazideTablet50 mg/1OralLeading Pharma, Llc2007-03-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralAmerican Health Packaging2009-09-03Not applicableUs
HydrochlorothiazideTablet25 mg/1OralAidarex Pharmaceuticals LLC2002-03-29Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralMed Health Pharma, LLC2011-01-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralCardinal Health1982-01-01Not applicableUs
HydrochlorothiazideTablet25 mg/1OralSt Marys Medical Park Pharmacy2007-05-01Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralReady Meds2010-03-15Not applicableUs
HydrochlorothiazideTablet25 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-06-01Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralPhysicians Total Care, Inc.2002-05-23Not applicableUs
HydrochlorothiazideCapsule, gelatin coated12.5 mg/1OralJUBILANT CADISTA PHARMACEUTICALS, INC.2008-02-11Not applicableUs
HydrochlorothiazideTablet50 mg/1Oralbryant ranch prepack2010-08-20Not applicableUs
HydrochlorothiazideTablet25 mg/1OralContract Pharmacy Services Pa2010-11-09Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralPreferred Pharmaceuticals, Inc.2014-06-16Not applicableUs
HydrochlorothiazideTablet50 mg/1OralBlenheim Pharmacal, Inc.2013-10-01Not applicableUs
HydrochlorothiazideTablet12.5 mg/1OralHeritage Pharmaceuticals Inc.2011-01-03Not applicableUs
HydrochlorothiazideTablet25 mg/1OralScie Gen Pharmaceuticals, Inc.2014-07-23Not applicableUs
HydrochlorothiazideTablet50 mg/1OralAvera Mc Kennan Hospital2015-04-03Not applicableUs
HydrochlorothiazideCapsule12.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-08-07Not applicableUs
HydrochlorothiazideTablet25 mg/1OralNu Care Pharmaceuticals, Inc.2013-04-10Not applicableUs
HydrochlorothiazideTablet25 mg/1OralA S Medication Solutions2002-03-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DichlotrideM & H
EsidrexNovartis
HydrodiurilMerck
HydroDIURILMerck
Brand mixtures
NameLabellerIngredients
AccureticParke Davis Div Of Pfizer Inc
Accuretic 10/12.5 mgPfizer Canada Inc
Accuretic 20/12.5 mgPfizer Canada Inc
Accuretic 20/25 mgPfizer Canada Inc
Ach-telmisartan HctzAccord Healthcare Inc
Act Candesartan/hctActavis Pharma Company
Act Irbesartan/hctActavis Pharma Company
Act Losartan/hctActavis Pharma Company
Act Telmisartan/hctActavis Pharma Company
Actelsar HctActavis Group Hf
AldactazideG.D. Searle LLC Division of Pfizer Inc
Aldactazide 25Pfizer Canada Inc
Aldactazide 50Pfizer Canada Inc
Aldoril 15 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Aldoril 25 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Altace HctValeant Canada Lp Valeant Canada S.E.C.
Alti-amiloride HctzAltimed Pharma Inc.
Ami-hydro TabPro Doc Limitee
Amiloride Hydrochloride and HydrochlorothiazideMylan Pharmaceuticals Inc.
Amlodipine, Valsartan and HydrochlorothiazideTorrent Pharmaceuticals Limited
Amlodipine, Valsartan, and HydrochlorothiazideTeva Pharmaceuticals USA Inc
Amlodipine, Valsartan, HydrochlorothiazideSandoz Inc
AmturnideNovartis Pharmaceuticals Corporation
Apo Methazide 15Apotex Inc
Apo Methazide 25Apotex Inc
Apo TriazideApotex Inc
Apo-amilzide TabApotex Inc
Apo-candesartan/hctzApotex Inc
Apo-cilazapril/hctzApotex Inc
Apo-enalapril Maleate/hctzApotex Inc
Apo-irbesartan/hctzApotex Inc
Apo-lisinopril/hctzApotex Inc
Apo-losartan/hctzApotex Inc
Apo-quinapril/hctzApotex Inc
Apo-ramipril/hctzApotex Inc
Apo-spirozide TabApotex Inc
Apo-telmisartan/hctzApotex Inc
Apo-valsartan/hctzApotex Inc
Atacand HctPhysicians Total Care, Inc.
Atacand PlusAstrazeneca Canada Inc
Auro-candesartan HctAuro Pharma Inc
Auro-irbesartan HctAuro Pharma Inc
Auro-losartan HctAuro Pharma Inc
Auro-telmisartan HctzAuro Pharma Inc
Auro-valsartan HctAuro Pharma Inc
Ava-irbesartan/hctzAvanstra Inc
Ava-lisinopril HctAvanstra Inc
Ava-valsartan HctAvanstra Inc
AvalidePhysicians Total Care, Inc.
Avalide 150/12.5 mgSanofi Aventis Canada Inc
Avalide 300/12.5 mgSanofi Aventis Canada Inc
Benazepril Hydrochloride and HydrochlorothiazideMylan Pharmaceuticals Inc.
Benicar HctLake Erie Medical & Surgical Supply DBA Quality Care Products LLC
Bisoprolol Fumarate and HydrochlorothiazideMylan Pharmaceuticals Inc.
Candesartan Cilexetil and HydrochlorothiazideMylan Pharmaceuticals Inc.
Candesartan Cilexetil and Hydrochlorothiazide TabletsAlembic Pharmaceuticals Limited
Candesartan Cilexetil-hydrochlorothiazidePar Pharmaceutical Inc.
Candesartan HctSivem Pharmaceuticals Ulc
Candesartan-hctzPro Doc Limitee
Candesartan/hctzSanis Health Inc
Captopril and HydrochlorothiazideMylan Phamaceuticals Inc.
Diovan HctNovartis Pharmaceuticals Corporation
Diovan-hctNovartis Pharmaceuticals Canada Inc
Dom-irbesartan-hctzDominion Pharmacal
DutoprolAstra Zeneca Lp
DyazideCardinal Health
Dyazide TabSmithkline Beecham Pharma Division Of Smithkline Beecham Inc
Enalapril Maleate and HydrochlorothiazideTeva Pharmaceuticals USA Inc
Enalapril/hctzFrosst A Division Of Merck Canada Inc
Exforge HctNovartis Pharmaceuticals Corporation
Fosinopril Sodium and HydrochlorothiazideHeritage Pharmaceuticals Inc.
Gd-quinapril HctzGenmed A Division Of Pfizer Canada Inc
Hydropres 25 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Hydropres 50 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
HyzaarMerck Sharp & Dohme Corp.
Hyzaar 50/12.5mgMerck Canada Inc
Hyzaar DS 100/25 mgMerck Canada Inc
Imprida HctNovartis Europharm Ltd.
Inderide-40 TabWyeth Ayerst Canada Inc.
Inderide-80 TabWyeth Ayerst Canada Inc.
Inhibace Plus - TabHoffmann La Roche Limited
Ipg-candesartan + HctInternational Pharmaceutical Generics Ltd
Irbesartan and HydrochlorothiazideTeva Pharmaceuticals USA Inc
Irbesartan HctSivem Pharmaceuticals Ulc
Irbesartan Hydrochlorothiazide BmsBristol Myers Squibb Pharma Eeig
Irbesartan-hctzPro Doc Limitee
Irbesartan/hctActavis Pharma Company
Irbesartan/hctzSanis Health Inc
Jamp-irbesartan and HydrochlorothiazideJamp Pharma Corporation
Jamp-losartan HctzJamp Pharma Corporation
KarvezideSanofi Aventis Groupe
Lisinopril and HctzNorthwind Pharmaceuticals, LLC
Lisinopril and HydrochlorothiazideIVAX Pharmaceuticals, Inc.
Lisinopril and HydrochlorthiazideREMEDYREPACK INC.
Lisinopril With HydrochlorothiazidePd Rx Pharmaceuticals, Inc.
Lisinopril/hctz (type Z)Sanis Health Inc
Lisnopril/hctz (type P)Sanis Health Inc
Lopressor HctValidus Pharmaceuticals LLC
Losartan HctSivem Pharmaceuticals Ulc
Losartan Potassium and HydrochlorothiazideTeva Pharmaceuticals USA Inc
Losartan-hctzPro Doc Limitee
Losartan/hctActavis Pharma Company
Losartan/hctzSanis Health Inc
Lotensin HctValidus Pharmaceuticals LLC
MaxzideMylan Pharmaceuticals Inc.
Maxzide-25Mylan Pharmaceuticals Inc.
Methyldopa and HydrochlorothiazideMylan Pharmaceuticals Inc.
Metoprolol Succinate and HydrochlorothiazideSolubiomix
Metoprolol Tartrate and HydrochlorothiazidePhysicians Total Care, Inc.
Metoprolol Tartrate and Hydrochlorothiazide 100 Mg-25 mgNorth Star Rx Llc
Metoprolol Tartrate and Hydrochlorothiazide 100 Mg-50 mgNorth Star Rx Llc
Metoprolol Tartrate and Hydrochlorothiazide 50 Mg-25 mgNorth Star Rx Llc
Micardis HctBoehringer Ingelheim Pharmaceuticals, Inc.
Micardis PlusBoehringer Ingelheim (Canada) Ltd Ltee
Mint-irbesartan/hctzMint Pharmaceuticals Inc
Mint-losartan/hctzMint Pharmaceuticals Inc
Mint-losartan/hctz DSMint Pharmaceuticals Inc
ModuretPrempharm Inc
Moexipril Hydrochloride and HydrochlorothiazideHeritage Pharmaceuticals Inc.
Mylan-amilazideMylan Pharmaceuticals Ulc
Mylan-candesartan HctzMylan Pharmaceuticals Ulc
Mylan-irbesartan HctzMylan Pharmaceuticals Ulc
Mylan-lisinopril HctzMylan Pharmaceuticals Ulc
Mylan-losartan HctzMylan Pharmaceuticals Ulc
Mylan-telmisartan HctzMylan Pharmaceuticals Ulc
Mylan-valsartan HctzMylan Pharmaceuticals Ulc
NovamilorTeva Canada Limited
Novo-cilazapril/hctzTeva Canada Limited
Novo-doparil 15 TabNovopharm Limited
Novo-doparil 25 TabNovopharm Limited
Novo-valsartan/hctzTeva Canada Limited
Ntp-irbesartan/hctzTeva Canada Limited
Ntp-lisinopril/hctz (type P)Teva Canada Limited
Ntp-lisinopril/hctz (type Z)Teva Canada Limited
Ntp-telmisartan HctzTeva Canada Limited
Nu-amilzide 5/50 Mg TabNu Pharm Inc
Nu-lisinopril/hctzNu Pharm Inc
Nu-triazide Tab 50 Mg/25 mgNu Pharm Inc
Olmesartan Medoxmil and HydrochlorothiazideMylan Pharmaceuticals Inc.
Olmesartan Medoxomil / Amlodipine Besylate / HydrochlorothiazidePar Pharmaceutical, Inc.
Olmesartan Medoxomil and HydrochlorothiazideSun Pharmaceutical Industries, Inc.
Olmesartan Medoxomil, Amlodipine and HydrochlorothiazideSun Pharmaceutical Industries, Inc.
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 20/5/12.5 mgTorrent Pharmaceuticals Limited
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/10/12.5 mgTorrent Pharmaceuticals Limited
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/10/25 mgTorrent Pharmaceuticals Limited
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/5/12.5 mgTorrent Pharmaceuticals Limited
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40/5/25 mgTorrent Pharmaceuticals Limited
Olmetec PlusMerck Canada Inc
Pendo-irbesartan-hctzPendopharm Division Of De Pharmascience Inc
Pendo-telmisartan-hctzPendopharm Division Of De Pharmascience Inc
Penta-amiloride Hctz TabletsPentapharm Ltd.
Penta-triamterene Hctz TabletsPentapharm Ltd.
PMS-candesartan HctzPharmascience Inc
PMS-dopazide 15 TabPharmascience Inc
PMS-dopazide-25 TabPharmascience Inc
PMS-irbesartan-hctzPharmascience Inc
PMS-losartan-hctzPharmascience Inc
PMS-ramipril-hctzPharmascience Inc
PMS-telmisartan-hctzPharmascience Inc
PMS-valsartan-hctzPharmascience Inc
PrinzideMerck Canada Inc
Pro-triazidePro Doc Limitee
Propranolol Hydrochloride and HydrochlorothiazideMylan Pharmaceuticals Inc.
Q-valsartan HctzQd Pharmaceuticals Ulc
Quinapril and Hydrochlorothiazide 10/12.5Cipla USA Inc.
Quinapril and Hydrochlorothiazide 20/12.5Cipla USA Inc.
Quinapril and Hydrochlorothiazide 20/25Cipla USA Inc.
Quinapril HCl and HydrochlorothiazideGavis Pharmaceuticals, LLC.
Quinapril Hydrochloride and HydrochlorothiazideCamber Pharmaceuticals
Quinapril Hydrochloride/hydrochlorothiazideLake Erie Medical DBA Quality Care Products LLC
Ramipril-hctzSanis Health Inc
Ran-irbesartan HctzRanbaxy Pharmaceuticals Canada Inc.
Ran-ramipril HctzRanbaxy Pharmaceuticals Canada Inc.
Ran-telmisartan HctzRanbaxy Pharmaceuticals Canada Inc.
Rasilez HctNovartis Pharmaceuticals Canada Inc
Ratio-irbesartan HctzTeva Canada Limited
Ratio-losartan HctzTeva Canada Limited
Riva-amilzide 5/50 mgLaboratoire Riva Inc
Riva-zide 50/25mg TabletsLaboratoire Riva Inc
Sandoz Candesartan PlusSandoz Canada Incorporated
Sandoz Irbesartan HctSandoz Canada Incorporated
Sandoz Lisinopril HctSandoz Canada Incorporated
Sandoz Losartan HctSandoz Canada Incorporated
Sandoz Losartan Hct DSSandoz Canada Incorporated
Sandoz Telmisartan HctSandoz Canada Incorporated
Sandoz Valsartan HctSandoz Canada Incorporated
Septa-candesartan HctzSepta Pharmaceuticals Inc
Septa-losartan HctzSepta Pharmaceuticals Inc
Ser-AP-ES TabNovartis Pharmaceuticals Canada Inc
Spironolactone and HydrochlorothiazideMylan Pharmaceuticals Inc.
Tekturna HctNovartis Pharmaceuticals Corporation
Telmisartan and HydrochlorothiazideRoxane Laboratories, Inc.
Telmisartan and Hydrochlorothiazide 40 Mg/12.5 mgAlembic Pharmaceuticals Limited
Telmisartan and Hydrochlorothiazide 80 Mg/12.5 mgAlembic Pharmaceuticals Limited
Telmisartan and Hydrochlorothiazide 80 Mg/25 mgAlembic Pharmaceuticals Limited
Telmisartan and HydrochlorthiazideTorrent Pharmaceuticals Limited
Telmisartan HctzSivem Pharmaceuticals Ulc
Telmisartan-hctzPro Doc Limitee
Telmisartan/hctzSanis Health Inc
Teva-candesartan/hctzTeva Canada Limited
Teva-enalapril/hctzTeva Canada Limited
Teva-irbesartan/hctzTeva Canada Limited
Teva-lisinopril/hctz (type P)Teva Canada Limited
Teva-lisinopril/hctz (type Z)Teva Canada Limited
Teva-losartan/hctzTeva Canada Limited
Teva-ramipril/hctzTeva Canada Limited
Teva-spironolactone/hctzTeva Canada Limited
Teva-telmisartan HctzTeva Canada Limited
Teva-triamterene/hctzTeva Canada Limited
Teva-valsartan/hctzTeva Canada Limited
Teveten HctAbb Vie Inc.
Teveten PlusBgp Pharma Ulc
Timolide TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Torrent-telmisartan and HydrochlorothiazideTorrent Pharmaceuticals Limited
Triamterene and HydrochlorothiazideKAISER FOUNDATION HOSPITALS
Triamterene HydrochlorothiazideKAISER FOUNDATION HOSPITALS
TribenzorDaiichi Sankyo, Inc.
Valsartan and HydrochlorothiazideMylan Pharmaceuticals Inc.
Valsartan HctSanis Health Inc
Valsartan HctzNorthwind Pharmaceuticals
Valsartan-hctzPro Doc Limitee
Van-irbesartan-hctzVanc Pharmaceuticals Inc
Van-losartan-hctzVanc Pharmaceuticals Inc
Van-telmisartan-hctzVanc Pharmaceuticals Inc
VasereticValeant Pharmaceuticals North America LLC
Viskazide 10/25tabTribute Pharmaceuticals Canada Inc
Viskazide 10/50tabTribute Pharmaceuticals Canada Inc
ZestoreticAstra Zeneca Pharmaceuticals Lp
Zestoretic Tab 10/12.5mgAstrazeneca Canada Inc
Zestoretic Tab 20/12.5mgAstrazeneca Canada Inc
Zestoretic Tab 20/25mgAstrazeneca Canada Inc
ZiacTeva Women's Health, Inc.
Zinda-candesartan/hydrochlorothiazideZinda Pharma Limited
Zinda-telmisartan/ HctzZinda Pharma Limited
SaltsNot Available
Categories
UNII0J48LPH2TH
CAS number58-93-5
WeightAverage: 297.739
Monoisotopic: 296.964474846
Chemical FormulaC7H8ClN3O4S2
InChI KeyJZUFKLXOESDKRF-UHFFFAOYSA-N
InChI
InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)
IUPAC Name
6-chloro-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Pharmacology
IndicationFor the treatment of high blood pressure and management of edema.
Structured Indications
PharmacodynamicsThiazides such as hydrochlorothiazide promote water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
Mechanism of actionHydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, hydrochlorothiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron.
TargetKindPharmacological actionActionsOrganismUniProt ID
Solute carrier family 12 member 3Proteinyes
inhibitor
HumanP55017 details
Carbonic anhydrase 1Proteinunknown
inhibitor
HumanP00915 details
Carbonic anhydrase 2Proteinunknown
inhibitor
HumanP00918 details
Carbonic anhydrase 4Proteinunknown
inhibitor
HumanP22748 details
Carbonic anhydrase 9Proteinunknown
inhibitor
HumanQ16790 details
Carbonic anhydrase 12Proteinunknown
inhibitor
HumanO43570 details
Calcium-activated potassium channel subunit alpha-1Proteinunknown
other/unknown
HumanQ12791 details
Related Articles
Absorption50-60%
Volume of distributionNot Available
Protein binding67.9%
Metabolism

Hydrochlorothiazide is not metabolized.

Route of eliminationHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
Half life5.6 and 14.8 hours
ClearanceNot Available
ToxicityThe most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Hydrochlorothiazide Action PathwayDrug actionSMP00100
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Hydrochlorothiazide.Experimental, Illicit
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Hydrochlorothiazide.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Hydrochlorothiazide.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Hydrochlorothiazide.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydrochlorothiazide.Withdrawn
AcetovanilloneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Acetovanillone.Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acetyldigitoxin.Approved
Acetylsalicylic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Adapalene.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Hydrochlorothiazide.Experimental
AlclometasoneAlclometasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrochlorothiazide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Hydrochlorothiazide.Experimental
AlfacalcidolHydrochlorothiazide may increase the hypercalcemic activities of Alfacalcidol.Approved, Nutraceutical
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Hydrochlorothiazide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Aliskiren.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Hydrochlorothiazide.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrochlorothiazide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Hydrochlorothiazide.Experimental, Illicit
AlprenololAlprenolol may increase the hypotensive activities of Hydrochlorothiazide.Approved, Withdrawn
AmbrisentanHydrochlorothiazide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved
AmifostineHydrochlorothiazide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Hydrochlorothiazide.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Hydrochlorothiazide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Amyl Nitrite.Approved
AnecortaveAnecortave may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
AnisodamineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Antipyrine.Approved
AnvirzelThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Anvirzel.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Hydrochlorothiazide.Approved
ApremilastThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Hydrochlorothiazide.Approved
Atracurium besylateThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Hydrochlorothiazide.Investigational
BalsalazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Barnidipine.Approved
BeclomethasoneBeclomethasone may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
BenactyzineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilHydrochlorothiazide may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Hydrochlorothiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
BenoxaprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Benzatropine.Approved
BepridilHydrochlorothiazide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Hydrochlorothiazide.Approved
BethanidineBethanidine may increase the hypotensive activities of Hydrochlorothiazide.Approved
Betulinic AcidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Betulinic Acid.Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Hydrochlorothiazide.Experimental, Illicit, Withdrawn
BimatoprostBimatoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
BiperidenThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Hydrochlorothiazide.Approved
BortezomibThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Hydrochlorothiazide.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Hydrochlorothiazide.Approved
BromfenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Bromocriptine.Approved, Investigational
BucillamineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Hydrochlorothiazide.Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hydrochlorothiazide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Bupivacaine.Approved, Investigational
BupranololHydrochlorothiazide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydrochlorothiazide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hydrochlorothiazide.Approved, Illicit, Vet Approved
CalcidiolHydrochlorothiazide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolHydrochlorothiazide may increase the hypercalcemic activities of Calcipotriol.Approved
CalcitriolHydrochlorothiazide may increase the hypercalcemic activities of Calcitriol.Approved, Nutraceutical
CalciumHydrochlorothiazide may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetateHydrochlorothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium carbonateHydrochlorothiazide may decrease the excretion rate of Calcium carbonate which could result in a higher serum level.Approved
Calcium ChlorideHydrochlorothiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
Calcium citrateHydrochlorothiazide may decrease the excretion rate of Calcium citrate which could result in a higher serum level.Approved
Calcium glubionateHydrochlorothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateHydrochlorothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateHydrochlorothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Hydrochlorothiazide.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Hydrochlorothiazide.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carbetocin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Hydrochlorothiazide.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
CarprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Hydrochlorothiazide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Hydrochlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydrochlorothiazide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Hydrochlorothiazide.Approved
CholecalciferolHydrochlorothiazide may increase the hypercalcemic activities of Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydrochlorothiazide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cilnidipine.Approved
CitalopramCitalopram may increase the hyponatremic activities of Hydrochlorothiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Hydrochlorothiazide.Approved
ClonixinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Hydrochlorothiazide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Conivaptan.Approved, Investigational
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Hydrochlorothiazide.Approved
CurcuminThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Curcumin.Investigational
CyclopentolateThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cyclophosphamide.Approved, Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Hydrochlorothiazide.Approved
D-LimoneneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with D-Limonene.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Hydrochlorothiazide.Investigational
DarifenacinThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinHydrochlorothiazide may increase the hypotensive activities of Debrisoquin.Approved
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Hydrochlorothiazide.Investigational
DeserpidineHydrochlorothiazide may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Desflurane.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Hydrochlorothiazide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Hydrochlorothiazide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Hydrochlorothiazide.Vet Approved
DexetimideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Hydrochlorothiazide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydrochlorothiazide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Hydrochlorothiazide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hydrochlorothiazide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Hydrochlorothiazide.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dicyclomine.Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DiflunisalThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin.Approved
DihydralazineHydrochlorothiazide may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydrochlorothiazide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Hydrochlorothiazide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydrochlorothiazide.Experimental, Illicit
DihydrotachysterolHydrochlorothiazide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Hydrochlorothiazide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hydrochlorothiazide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Hydrochlorothiazide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
DofetilideHydrochlorothiazide may increase the QTc-prolonging activities of Dofetilide.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Hydrochlorothiazide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Hydrochlorothiazide.Approved
DoxercalciferolHydrochlorothiazide may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Hydrochlorothiazide.Investigational
DroxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydrochlorothiazide.Approved
DuloxetineHydrochlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ebselen.Investigational
EfonidipineHydrochlorothiazide may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Hydrochlorothiazide.Approved, Vet Approved
EnalaprilatHydrochlorothiazide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Hydrochlorothiazide.Approved
EpoprostenolHydrochlorothiazide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Hydrochlorothiazide.Approved
EquileninEquilenin may increase the hypokalemic activities of Hydrochlorothiazide.Experimental
EquilinEquilin may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ErgocalciferolHydrochlorothiazide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Hydrochlorothiazide.Approved
EstroneEstrone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hydrochlorothiazide.Approved
EtanerceptThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved
EthopropazineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Hydrochlorothiazide.Approved, Illicit
EtodolacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Hydrochlorothiazide.Approved
EtoricoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Hydrochlorothiazide.Illicit, Vet Approved
Evening primrose oilThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
exisulindThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Hydrochlorothiazide.Approved
FenoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydrochlorothiazide.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Fimasartan.Approved
FloctafenineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FlunixinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Flunixin.Vet Approved
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FlurbiprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
FluvoxamineFluvoxamine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Hydrochlorothiazide.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Hydrochlorothiazide.Approved, Vet Approved
Gallamine TriethiodideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Gallamine Triethiodide.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydrochlorothiazide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Hydrochlorothiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrochlorothiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrochlorothiazide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrochlorothiazide.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Hydrochlorothiazide.Approved
GlycopyrroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Hydrochlorothiazide.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Hydrochlorothiazide.Approved
GuanethidineHydrochlorothiazide may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Hydrochlorothiazide.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Hydrochlorothiazide.Approved, Illicit
HexamethoniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved
HigenamineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Higenamine.Investigational
HMPL-004The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with HMPL-004.Investigational
HomatropineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Hydrochlorothiazide.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Hydralazine.Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydrochlorothiazide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Hydrochlorothiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydrochlorothiazide.Approved, Illicit
HyoscyamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Hydrochlorothiazide.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Hydrochlorothiazide.Approved
IndenololHydrochlorothiazide may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminHydrochlorothiazide may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrochlorothiazide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrochlorothiazide.Approved
Ipratropium bromideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Hydrochlorothiazide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Isoflurane.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydrochlorothiazide.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Hydrochlorothiazide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
IvabradineHydrochlorothiazide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Kebuzone.Experimental
KetanserinHydrochlorothiazide may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Hydrochlorothiazide.Approved
KetoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Hydrochlorothiazide.Approved
LacidipineHydrochlorothiazide may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
LeflunomideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Levobupivacaine.Approved
LevodopaHydrochlorothiazide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hydrochlorothiazide.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Hydrochlorothiazide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydrochlorothiazide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Levosimendan.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Hydrochlorothiazide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Hydrochlorothiazide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Hydrochlorothiazide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lisofylline.Investigational
LithiumHydrochlorothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Hydrochlorothiazide.Illicit
LofexidineHydrochlorothiazide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Hydrochlorothiazide.Approved
LoxoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanHydrochlorothiazide may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineHydrochlorothiazide may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Hydrochlorothiazide.Approved, Investigational
MasoprocolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Masoprocol.Approved
ME-609ME-609 may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
Mefenamic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Hydrochlorothiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Hydrochlorothiazide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Hydrochlorothiazide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Hydrochlorothiazide.Approved, Illicit
MethanthelineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Methantheline.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Hydrochlorothiazide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydrochlorothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Hydrochlorothiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Hydrochlorothiazide.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Metipranolol.Approved
MetixeneThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Metixene.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Hydrochlorothiazide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Hydrochlorothiazide.Approved, Investigational
MetyrosineHydrochlorothiazide may increase the hypotensive activities of Metyrosine.Approved
MibefradilHydrochlorothiazide may increase the hypotensive activities of Mibefradil.Withdrawn
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Hydrochlorothiazide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Hydrochlorothiazide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Hydrochlorothiazide.Approved
MinaprineMinaprine may increase the hypotensive activities of Hydrochlorothiazide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Hydrochlorothiazide.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
MizoribineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Hydrochlorothiazide.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Hydrochlorothiazide.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Hydrochlorothiazide.Approved
MometasoneMometasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Hydrochlorothiazide.Approved, Investigational
MoxonidineHydrochlorothiazide may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mycophenolic acid.Approved
N-butylscopolammonium bromideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nabilone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nafamostat.Investigational
NaftifineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naftifine.Approved
NaftopidilHydrochlorothiazide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hydrochlorothiazide.Approved
NaproxenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
NCX 4016The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Hydrochlorothiazide.Approved
NicorandilNicorandil may increase the hypotensive activities of Hydrochlorothiazide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nifedipine.Approved
Niflumic AcidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineHydrochlorothiazide may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineHydrochlorothiazide may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Hydrochlorothiazide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Hydrochlorothiazide.Approved
NitrendipineHydrochlorothiazide may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nitric Oxide.Approved
NitroaspirinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Hydrochlorothiazide.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Hydrochlorothiazide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Hydrochlorothiazide.Approved, Illicit
NVA237The serum concentration of Hydrochlorothiazide can be increased when it is combined with NVA237.Investigational
ObinutuzumabHydrochlorothiazide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
Oleoyl estroneOleoyl estrone may increase the hypokalemic activities of Hydrochlorothiazide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Hydrochlorothiazide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
OlopatadineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Hydrochlorothiazide.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Hydrochlorothiazide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved
OrgoteinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Orphenadrine.Approved
OuabainThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Oxcarbazepine.Approved
OxprenololHydrochlorothiazide may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hydrochlorothiazide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydrochlorothiazide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Paclitaxel.Approved, Vet Approved
PancuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ParecoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Hydrochlorothiazide.Approved
ParicalcitolHydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydrochlorothiazide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
PentoliniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Hydrochlorothiazide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Hydrochlorothiazide.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Hydrochlorothiazide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Hydrochlorothiazide.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Hydrochlorothiazide.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Hydrochlorothiazide.Approved
PhenylbutazoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilHydrochlorothiazide may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Hydrochlorothiazide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Pipamperone.Approved
PipecuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
PirenzepineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Hydrochlorothiazide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Hydrochlorothiazide.Approved
PiroxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
PolythiazideHydrochlorothiazide may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Nutraceutical
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Hydrochlorothiazide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Hydrochlorothiazide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Hydrochlorothiazide.Experimental
PrimidonePrimidone may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
ProcyclidineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Procyclidine.Approved
PropacetamolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Propacetamol.Approved
PropanthelineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Hydrochlorothiazide.Approved, Investigational
PTC299The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Hydrochlorothiazide.Approved, Investigational
QuinidineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Hydrochlorothiazide.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Hydrochlorothiazide.Approved
RasagilineRasagiline may increase the hypotensive activities of Hydrochlorothiazide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydrochlorothiazide.Approved
RemikirenRemikiren may increase the hypotensive activities of Hydrochlorothiazide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
RescinnamineHydrochlorothiazide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydrochlorothiazide.Approved
ResveratrolThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Resveratrol.Experimental, Investigational
RilmenidineHydrochlorothiazide may increase the hypotensive activities of Rilmenidine.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Riociguat.Approved
RisperidoneHydrochlorothiazide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Hydrochlorothiazide.Approved
RituximabHydrochlorothiazide may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Hydrochlorothiazide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
SalsalateThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salsalate.Approved
SaprisartanHydrochlorothiazide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved
ScopolamineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine butylbromide.Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational, Vet Approved
SelexipagHydrochlorothiazide may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Seratrodast.Approved, Investigational
SertralineSertraline may increase the hyponatremic activities of Hydrochlorothiazide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
SitaxentanHydrochlorothiazide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sodium Nitrite.Approved
SolifenacinThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Solifenacin.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Hydrochlorothiazide.Approved
SpiraprilHydrochlorothiazide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Hydrochlorothiazide.Approved
SRT501The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydrochlorothiazide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Hydrochlorothiazide.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Hydrochlorothiazide.Approved, Investigational
TemocaprilHydrochlorothiazide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved
TeriflunomideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Teriflunomide.Approved
TerlipressinHydrochlorothiazide may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Hydrochlorothiazide.Investigational
ThiopentalThiopental may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Thioridazine.Approved
Tiaprofenic acidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneHydrochlorothiazide may increase the hypotensive activities of Tibolone.Approved
TicrynafenHydrochlorothiazide may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Hydrochlorothiazide.Approved
TinoridineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hydrochlorothiazide.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrochlorothiazide.Approved
TolazolineTolazoline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrochlorothiazide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Hydrochlorothiazide.Approved
TolterodineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateHydrochlorothiazide may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Hydrochlorothiazide.Approved
ToremifeneHydrochlorothiazide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydrochlorothiazide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Hydrochlorothiazide.Approved
TranilastThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hydrochlorothiazide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Hydrochlorothiazide.Approved
TravoprostTravoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Hydrochlorothiazide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Hydrochlorothiazide.Approved
TrichlormethiazideHydrochlorothiazide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinHydrochlorothiazide may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Trimethaphan.Approved
Trisalicylate-cholineThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Trisalicylate-choline.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Hydrochlorothiazide.Withdrawn
TropicamideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved, Investigational
UmeclidiniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Umeclidinium.Approved
UnoprostoneHydrochlorothiazide may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanHydrochlorothiazide may increase the hypotensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Hydrochlorothiazide.Approved
VecuroniumThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Hydrochlorothiazide.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydrochlorothiazide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
VinpocetineHydrochlorothiazide may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Hydrochlorothiazide.Approved, Investigational
XylometazolineHydrochlorothiazide may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Hydrochlorothiazide.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Hydrochlorothiazide.Withdrawn
ZomepiracThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Avoid natural licorice.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Increase potassium intake; add a banana or orange juice; unless instructed otherwise.
  • Take with food.
References
Synthesis Reference

Frederic J. Nugent, John K. C. Yen, “Process for preparing the combination products of triamterene and hydrochlorothiazide.” U.S. Patent US4804540, issued July, 1987.

US4804540
General ReferencesNot Available
External Links
ATC CodesC09DX03C09XA52C09DX01C03AB03C03EA01C03AX01C03AA03C09XA54
AHFS Codes
  • 40:28.20
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9202
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8956
P-glycoprotein substrateNon-substrate0.6533
P-glycoprotein inhibitor INon-inhibitor0.8624
P-glycoprotein inhibitor IINon-inhibitor0.8688
Renal organic cation transporterNon-inhibitor0.8416
CYP450 2C9 substrateNon-substrate0.7664
CYP450 2D6 substrateNon-substrate0.8333
CYP450 3A4 substrateNon-substrate0.6217
CYP450 1A2 substrateNon-inhibitor0.9401
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9252
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9569
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9036
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7986
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity2.0666 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9576
hERG inhibition (predictor II)Non-inhibitor0.9135
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc
  • Aurobindo pharma ltd
  • Cadista pharmaceuticals inc
  • Ipca laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Unichem laboratories ltd
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
  • Watson laboratories inc
  • Morton grove pharmaceuticals inc
  • Roxane laboratories inc
  • Novartis pharmaceuticals corp
  • Abc holding corp
  • Actavis elizabeth llc
  • Alra laboratories inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Barr laboratories inc
  • Caraco pharmaceutical laboratories ltd
  • Dava pharmaceuticals inc
  • Elkins sinn div ah robins co inc
  • Excellium pharmaceutical inc
  • Heather drug co inc
  • Heritage pharmaceuticals inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett holdings inc
  • Mm mast and co
  • Mutual pharmaceutical co inc
  • Private formulations inc
  • Sandoz inc
  • Solvay pharmaceuticals
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Tg united labs llc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • Warner chilcott div warner lambert co
  • Whiteworth towne paulsen inc
  • Halsey drug co inc
  • Merck and co inc
  • Abbott laboratories pharmaceutical products div
Packagers
Dosage forms
FormRouteStrength
Tablet, coatedOral
CapsuleOral12.5 mg/1
Capsule, gelatin coatedOral12.5 mg/1
TabletOral12.5 mg/1
TabletOral25 mg/25mg
TabletOral25 mg/1
TabletOral50 mg/50mg
TabletOral50 mg/1
Tablet, film coatedOral
TabletOral12.5 mg
TabletOral
CapsuleOral
TabletOral100 mg
TabletOral25 mg
TabletOral50 mg
Prices
Unit descriptionCostUnit
Niferex-150 Forte 100 80-70 mg capsule Box109.86USD box
Niferex 100 mg/5ml Elixir 236ml Bottle80.55USD bottle
Niferex 100 40-20 mg capsule Box77.99USD box
Capozide 50-25 mg tablet3.63USD tablet
Ziac 10-6.25 mg tablet3.6USD tablet
Ziac 2.5-6.25 mg tablet3.6USD tablet
Ziac 5-6.25 mg tablet3.6USD tablet
Capozide 50-15 tablet3.49USD tablet
Capozide 50-25 tablet3.49USD tablet
Capozide 50-15 mg tablet2.59USD tablet
Lotensin 20 mg tablet2.25USD tablet
Lotensin 10 mg tablet2.09USD tablet
Lotensin 40 mg tablet2.09USD tablet
Lotensin 5 mg tablet2.09USD tablet
Accuretic 20-12.5 mg tablet2.04USD tablet
Capozide 25-15 tablet2.03USD tablet
Capozide 25-25 tablet2.03USD tablet
Accuretic 10-12.5 mg tablet2.0USD tablet
Accuretic 20-25 mg tablet2.0USD tablet
Lotensin HCT 20-12.5 mg tablet1.97USD tablet
Lotensin HCT 10-12.5 mg tablet1.95USD tablet
Lotensin HCT 20-25 mg tablet1.94USD tablet
Lotensin hct 10-12.5 tablet1.9USD tablet
Lotensin hct 20-12.5 tablet1.9USD tablet
Lotensin hct 20-25 tablet1.9USD tablet
Lotensin hct 5-6.25 tablet1.9USD tablet
Niferex-150 150-50-50 mg capsule1.62USD capsule
Capozide 25-15 mg tablet1.51USD tablet
Lotensin HCT 5-6.25 mg tablet1.31USD tablet
Hydrochlorothiazide powder1.1USD g
Hydrochlorothiazide 12.5 mg tablet0.82USD tablet
Moduretic 5-50 mg tablet0.68USD tablet
Hydrochlorothiazide 12.5 mg capsule0.5USD capsule
Hydrochlorothiazide 50 mg tablet0.16USD tablet
Apo-Hydro 100 mg Tablet0.13USD tablet
Hydrochlorothiazide 25 mg tablet0.11USD tablet
Apo-Hydro 50 mg Tablet0.06USD tablet
Novo-Hydrazide 50 mg Tablet0.06USD tablet
Apo-Hydro 25 mg Tablet0.04USD tablet
Novo-Hydrazide 25 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5559111 No1998-07-212018-07-21Us
US5616599 Yes1996-10-252016-10-25Us
US5994348 Yes1995-12-072015-12-07Us
US6294197 Yes1997-12-182017-12-18Us
US6358986 No2000-01-102020-01-10Us
US6878703 Yes2002-05-192022-05-19Us
US8101599 No2003-05-162023-05-16Us
US8183295 No2003-05-162023-05-16Us
US8475839 Yes2003-11-162023-11-16Us
US8618172 No2008-07-132028-07-13Us
US8618174 No2001-11-152021-11-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point266-268U.S. Patent 3,163,645.
water solubility722 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-0.07HANSCH,C ET AL. (1995)
logS-2.62ADME Research, USCD
Caco2 permeability-6.06ADME Research, USCD
pKa7.9SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility2.24 mg/mLALOGPS
logP-0.16ALOGPS
logP-0.58ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)9.09ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity63.11 m3·mol-1ChemAxon
Polarizability25.35 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (11.5 KB)
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-052b-0090000000-aaa48e4702874457ae26View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-0r6r-0920000000-b129acf72e7dde12441eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-0a4i-1900000000-67f803f38aed0bd12adeView in MoNA
MSMass Spectrum (Electron Ionization)splash10-00r2-6490000000-3f5d9320308b823c6489View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiadiazines
Sub ClassBenzothiadiazines
Direct ParentBenzothiadiazines
Alternative Parents
Substituents
  • Benzothiadiazine
  • Benzenesulfonamide
  • Secondary aliphatic/aromatic amine
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name:
SLC12A3
Uniprot ID:
P55017
Molecular Weight:
113138.04 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Ran XW, Wang C, Dai F, Jiang JJ, Tong NW, Li XJ, Liang JZ: [A case of Gitelman's syndrome presenting with severe hypocalcaemia and hypokalemic periodic paralysis]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Jul;36(4):583-7. [PubMed:16078592 ]
  3. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension. 2005 Oct;46(4):758-65. Epub 2005 Sep 19. [PubMed:16172412 ]
  4. Abuladze N, Yanagawa N, Lee I, Jo OD, Newman D, Hwang J, Uyemura K, Pushkin A, Modlin RL, Kurtz I: Peripheral blood mononuclear cells express mutated NCCT mRNA in Gitelman's syndrome: evidence for abnormal thiazide-sensitive NaCl cotransport. J Am Soc Nephrol. 1998 May;9(5):819-26. [PubMed:9596079 ]
  5. Barry EL, Gesek FA, Kaplan MR, Hebert SC, Friedman PA: Expression of the sodium-chloride cotransporter in osteoblast-like cells: effect of thiazide diuretics. Am J Physiol. 1997 Jan;272(1 Pt 1):C109-16. [PubMed:9038817 ]
  6. Kurschat C, Heering P, Grabensee B: [Gitelman's syndrome: an important differential diagnosis of hypokalemia]. Dtsch Med Wochenschr. 2003 May 30;128(22):1225-8. [PubMed:12772080 ]
  7. Monroy A, Plata C, Hebert SC, Gamba G: Characterization of the thiazide-sensitive Na(+)-Cl(-) cotransporter: a new model for ions and diuretics interaction. Am J Physiol Renal Physiol. 2000 Jul;279(1):F161-9. [PubMed:10894798 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
  2. Couloigner V, Loiseau A, Sterkers O, Amiel C, Ferrary E: Effect of locally applied drugs on the endolymphatic sac potential. Laryngoscope. 1998 Apr;108(4 Pt 1):592-8. [PubMed:9546276 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Meyerson LR, Nesta D: [3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells. Biochem Pharmacol. 1991 Mar 15-Apr 1;41(6-7):995-1000. [PubMed:1901209 ]
  4. Schaeffer P, Vigne P, Frelin C, Lazdunski M: Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol. 1990 Jul 17;182(3):503-8. [PubMed:2226620 ]
  5. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
  2. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervical neoplasia.
Gene Name:
CA9
Uniprot ID:
Q16790
Molecular Weight:
49697.36 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide.
Gene Name:
CA12
Uniprot ID:
O43570
Molecular Weight:
39450.615 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Voltage-gated potassium channel activity
Specific Function:
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key ...
Gene Name:
KCNMA1
Uniprot ID:
Q12791
Molecular Weight:
137558.115 Da
References
  1. Tricarico D, Barbieri M, Mele A, Carbonara G, Camerino DC: Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats. FASEB J. 2004 Apr;18(6):760-1. Epub 2004 Feb 6. [PubMed:14766795 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739 ]
  2. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:54